- Home
- Media Center
- Press releases
- Innovative Medicine
Innovative Medicine
Real-World Data Published in Clinical Cardiology Show Consistent Safety Performance of Once-Daily XARELTO®
Findings Add to Rigorous Post-Marketing Safety Program for XARELTO® in Routine Clinical Practice
Johnson & Johnson Announces Start of Phase 1 Clinical Trial of Ebola Vaccine Regimen
Company Has Produced More Than 400,000 Vaccine Regimens for Use in Large-Scale Clinical Trials by April 2015
Janssen Submits New Drug Application to U.S. FDA for Three-Month Paliperidone Palmitate
First Long-Acting Treatment to be Used Four Times a Year for Schizophrenia in Adults
Real-World Data Presented at the American Heart Association (AHA) Scientific Sessions Underscore Hospitalization and Outpatient Cost-Savings for XARELTO® Compared to Standard of Care
Findings Add to Existing Data Showing XARELTO® Cost-Savings Value Across Indications
Johnson & Johnson Announces Completion Of Alios Biopharma Acquisition
Further Strengthens Existing Pipeline to Address Infectious Diseases
Janssen to Demonstrate Breadth of Oncology Portfolio with 41 Clinical Data Presentations at the 2014 American Society of Hematology (ASH) Annual Meeting
Note: This release corresponds to ASH abstracts 22, 31, 78, 84, 176, 327, 505, 2096, 2312, 3448, 3474, 4469, 4680
OLYSIO® (simeprevir) Gains Additional FDA Approval as Once-Daily, All-Oral Interferon- and Ribavirin-Free Treatment Option in Combination with Sofosbuvir for Adults with Genotype 1 Chronic Hepatitis C Infection
Expanded indication includes both treatment-naïve and treatment-experienced adult patients with or without cirrhosis